0

NCT00000726

Cytomegalovirus Retinitis

283

1

NCT00000726

Retinitis

9843

2

NCT00000333

Cocaine-Related Disorders

37604

3

NCT00000621

Emphysema

19688

4

NCT00000621

Pulmonary Emphysema

4300

0

NCT00000726

Foscarnet

529

1

NCT00000726

Phosphonoacetic Acid

2823

2

NCT00000179

Trazodone

656

3

NCT00000179

Haloperidol decanoate

502

4

NCT00000179

Haloperidol

502

NCT06207370

21

NCT00415051

45

NCT00584194

45

NCT00869713

45

NCT03609398

45

NCT00000102

United States

NCT00000105

United States

NCT00000110

United States

NCT00000116

United States

NCT00000117

United States

000032d4-fe13-4112-beb1-f256ac218516

NCT02239380

All

0

3 Months

No

Inclusion Criteria: - Subjects with status epilepticus or repetitive status epilepticus / cluster seizure who have seizures that can be evaluated by investigator's visual observations based on motor symptoms or who have seizures that can be evaluated by EEG. - Subjects with status epilepticus accompanied by generalized seizure, partial seizure or secondarily generalized seizure lasting 5 minutes or longer - Subjects with repetitive status epilepticus / cluster seizure accompanied by not less than 3 consecutive episodes of generalized seizure, partial seizure or secondarily generalized seizure in 1 hour. - Subjects not younger than 3 months (either gender is eligible for the study) Exclusion Criteria: - Subjects with known or suspected recurrent seizures due to illegal drug or alcohol withdrawal - Subjects with known history of hypersensitivity to lorazepam or benzodiazepine - Subjects with a known history of benzodiazepine abuse. - Subjects currently receiving lorazepam - Subjects with angle-closure glaucoma - Subjects with myasthenia gravis - Subjects with either of aspartate transaminase, alanine transaminase, total bilirubin, blood urea nitrogen, or creatinine at screening visit exceeding 2x the upper limit of normal of the institutional reference value (if the data is available) - Subjects with white blood cell count less than 3000/mm3 or neutrophil count less than 1500/mm3 at screening visit (if the data is available)

0000c2ab-2fd4-478b-bd36-5a743622e466

NCT00589485

Non-Probability Sample

All

0

18 Years

No

Inclusion Criteria: - Patients with painful and disabled knee joint resulting from osteoarthritis, rheumatoid arthritis, traumatic arthritis where one or more compartments are involved - Patients requiring correction of varus, valgus, or posttraumatic deformity - Patients requiring correction or revision of unsuccessful osteotomy, arthrodesis, or failure of previous joint replacement procedure Exclusion Criteria: - Infection, sepsis, and osteomyelitis

The study population will include patients who require total knee replacement.

0001264a-1354-4946-868a-7838224dd14b

NCT02060383

All

0

18 Years

No

Inclusion Criteria: - Patients greater than or equal to 18 years old - Confirmed diagnosis of Cushing's disease or acromegaly Exclusion Criteria: - Patients who require surgical intervention - Patients receiving DPP-4 inhibitors or GLP-1 receptor agonists within 4 weeks prior to study entry - HbA1c > 10 % at screening - Known hypersensitivity to somatostatin analogues Other protocol-defined inclusion/exclusion criteria may apply.

00013c19-631c-43f0-a80c-3e1876c4ce0f

NCT00505518

All

0

18 Years

No

Inclusion Criteria: - Clinical diagnosis of Major Depressive Disorder - Patient at South Cove Manor Nursing Home - Referred by nursing staff for psychiatric consultation Exclusion Criteria: - Not competent to participate in psychiatric interviews

00014719-3aca-4ca3-bd08-2e163777c3cf

NCT01742767

All

0

18 Years

75 Years

No

Inclusion Criteria: - Patients are eligible to be included in the study only if they meet all of the following criteria: 1. Histologically or cytologically confirmed diagnosis of non-squamous-cell non-small cell lung cancer (NSCLC) Stage IV (American Joint Committee on Cancer Staging Criteria [AJCC], Version 7, 2009) 2. No prior systemic chemotherapy for lung cancer 3. At least one unidimensionally measurable lesion meeting Response Evaluation Criteria in Solid Tumours (RECIST; version 1.1, Eisenhauer et al. 2009), longest diameter ≥10 mm with computed tomography (CT) scan [CT scan slice thickness no greater than 5 mm] , or ≥ 20 mm with chest x-ray. Positron emission tomography (PET) scans and ultrasounds should not be used. 4. ECOG performance status of 0 or 1 (Oken et al. 1982) 5. ≥ 18 years of age < 75 years 6. Adequate organ function, 7. Prior radiation therapy allowed to <25% of the bone marrow (Cristy and Eckerman 1987). Prior radiation to the whole pelvis is not allowed. Prior radiotherapy must be completed at least 4 weeks before study enrollment. Patients must have recovered from the acute toxic effects of the treatment prior to study enrollment. 8. Patient must understand and sign an informed consent document before the start of specific protocol procedures. 9. A pretreatment FFPE tumour biopsy must be available for central biomarker analysis. If consented by the patient and clinically feasible, a fresh pretreatment biopsy is obtained and submitted for central biomarker analysis. 10. Female patients with childbearing potential must use highly effective methods of contraception (combined oral contraceptives, hormon-releasing intrauterine contraceptive device, hormonal contraceptive implants, hormonal contraceptive injectables) or have sexual intercourse with a vasectomised partner only during and for 6 months after the study and their pregnancy test must be negative within 7 days prior to study enrollment. A female subject is considered to be of childbearing potential unless she is age ≥ 50 years and naturally amenorrhoeic for ≥ 2 year or unless she is surgically sterile. Male patients must agree to use condoms during the study and for 6 months after the study if their partner is of childbearing potential and does not use highly effective method of contraception. 11. Estimated life expectancy of 12 weeks 12. Patient compliance and geographic proximity that allow adequate follow up. Exclusion Criteria: - Patients will be excluded from the study if they meet any of the following criteria: 1. Active participation in other clinical studies or treatment with any experimental drug within 30 days prior to study enrollment or during study participation. 2. Patients with known somatic activating mutations of EGFR, as these patients should be offered EGFR- tyrosine kinase inhibitor (EGFR-TKI) treatment as first-line therapy. Detection of EGFR mutations and additional somatic mutations with relation to treatment will be performed centrally at the Universitätsklinikum Essen. In case immediate treatment initiation is required for medical reasons (such as superior vena cava syndrome, severely symptomatic disease) patients may be enrolled before results from EGFR testing are available. As EGFR-TKI treatment is equally effective in second-line therapy, such patients may remain on study treatment if a clinical benefit is derived. 3. Peripheral neuropathy of ³CTCAE Grade 1 4. Inability to comply with protocol or study procedures 5. A serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the patient's ability to complete the study. 6. A serious cardiac condition, such as myocardial infarction within 6 months prior to study enrollment, symptomatic coronary artery disease, cardiac arrhythmia, or other heart disease, as defined by the New York Heart Association Class III or IV (functional capacity) 7. Second primary malignancy that is clinically detectable at the time of consideration for study enrollment 8. Documented brain metastases unless the patient has completed successful local therapy for central nervous system metastases and has been off of corticosteroids for at least 4 weeks before enrollment. Brain imaging is required in symptomatic patients to rule out brain metastases,but is not required in asymptomatic patients 9. The effect of third space fluid, such as pleural effusion and ascites, on pemetrexed is unknown. In patients with clinically significant third space fluid, consideration should be given to draining the effusion prior to pemetrexed administration. 10. Significant weight loss (that is 10%) over the previous 6 weeks before study entry 11. Significant hearing function impairment, especially high-frequency hearing function impairment 12. Any active or uncontrolled infection 13. Concurrent administration of any other antitumour therapy 14. Inability to interrupt aspirin or other nonsteroidal anti-inflammatory agents, other than an aspirin dose <1.3 grams per day, for a 5-day period (8-day period for long-acting agents, such as piroxicam) 15. Inability or unwillingness to take folic acid or vitamin B12 supplementation 16. Inability to take corticosteroids 17. Hypersensitivity to cisplatinum or to any other platinum compound 18. Hypersensitivity to pemetrexed or to any of the excipients of ALIMTA® 19. Pregnant or breast-feeding patient 20. Yellow fever vaccination within the 30 days previous to study entry.

0

NCT00000726

NCT00000726

primary

1

NCT00000726

ACTG 015

org_study_id

2

NCT00000726

FDA 20D

external

3

NCT00000726

10991

external

4

NCT00001302

NCT00001302

primary

00003369-7f9d-4f3d-a5f3-8791add7ae73

75f6ae02-19ef-40a8-a704-f21a0f22782d

00003369-7f9d-4f3d-a5f3-8791add7ae73

c87b54dd-5857-4b63-abcb-c020d2b3d70a

00007119-bd3b-4baf-bfa2-2b8b72b0fbdc

99e58ce0-36fa-4716-96a3-bef08c6a6218

000087cb-d10e-429b-852b-a92a49bfc968

a0d6859d-79b5-4255-ac5f-b2d3b2631d35

000087cb-d10e-429b-852b-a92a49bfc968

a2e5d7c9-bddd-474b-a379-a5d1f7d9c21b

00003369-7f9d-4f3d-a5f3-8791add7ae73

NCT02696954

drug

Amodiaquine

Amodiaquine on Day 0, 1 and 2 Washout period: more than 6 weeks

00007119-bd3b-4baf-bfa2-2b8b72b0fbdc

NCT06975865

drug

Rilzabrutinib

Pharmaceutical form:Tablet -Route of administration:Oral

000087cb-d10e-429b-852b-a92a49bfc968

NCT05944952

drug

buprenorphine/naloxone

Participants will be dosed with buprenorphine/ naloxone strips

0000c179-971f-4b87-a009-fa35502ebc96

NCT02161965

drug

Warfarin

00010ba2-52e9-4928-966a-0b004d65e13e

NCT04605562

drug

Galunisertib

Administered orally

204862

00003369-7f9d-4f3d-a5f3-8791add7ae73

613

375157

00007119-bd3b-4baf-bfa2-2b8b72b0fbdc

28133

342379

000087cb-d10e-429b-852b-a92a49bfc968

921

342378

000087cb-d10e-429b-852b-a92a49bfc968

1183

174452

0000c179-971f-4b87-a009-fa35502ebc96

682

0

bf6f2649-31e2-4aee-b552-4bffe191f3b0

Elavil

1

f096be51-752d-4b08-829b-c90c16c00055

elavil plus prozac

2

95966692-f845-48e2-91ed-00b8e889ca85

Subutex

3

95966692-f845-48e2-91ed-00b8e889ca85

Suboxone

4

c07a15aa-8ddb-4fa3-9015-76bde5cff910

Zoloft

98127

000087cb-d10e-429b-852b-a92a49bfc968

157804

81453

00012692-6234-4c30-a7c1-cb1fde38bd99

489254

95794

0001d859-a82c-4a33-8072-0f4a7e4ba452

139536

72375

00046298-3c8b-432d-b463-62fb15cf588c

317307

72374

00046298-3c8b-432d-b463-62fb15cf588c

430009

NCT00017381

0

NCT00020670

0

NCT00091286

0

NCT00140556

0

NCT00176059

0

0

NCT00000726

National Institute of Allergy and Infectious Diseases (NIAID)

National Institute of Allergy & Infectious Diseases Niaid

nih

1

1

NCT00001302

National Cancer Institute (NCI)

National Cancer Institute Nci

nih

1

2

NCT00000179

National Institute on Aging (NIA)

National Institute on Aging Nia

nih

1

3

NCT00000333

Washington D.C. Veterans Affairs Medical Center

Washington Dc Veterans Affairs Medical Center

us_fed

0

4

NCT00000333

National Institute on Drug Abuse (NIDA)

National Institute on Drug Abuse Nida

nih

1

NCT00000102

Congenital Adrenal Hyperplasia: Calcium Channels as Therapeutic Targets

completed

treatment

This study will test the ability of extended release nifedipine (Procardia XL), a blood pressure medication, to permit a decrease in the dose of glucocorticoid medication children take to treat congenital adrenal hyperplasia (CAH).

This protocol is designed to assess both acute and chronic effects of the calcium channel antagonist, nifedipine, on the hypothalamic-pituitary-adrenal axis in patients with congenital adrenal hyperplasia. The multicenter trial is composed of two phases and will involve a double-blind, placebo-controlled parallel design. The goal of Phase I is to examine the ability of nifedipine vs. placebo to decrease adrenocorticotropic hormone (ACTH) levels, as well as to begin to assess the dose-dependency of nifedipine effects. The goal of Phase II is to evaluate the long-term effects of nifedipine; that is, can attenuation of ACTH release by nifedipine permit a decrease in the dosage of glucocorticoid needed to suppress the HPA axis? Such a decrease would, in turn, reduce the deleterious effects of glucocorticoid treatment in CAH.

0

0

NCT00000105

Vaccination With Tetanus and KLH to Assess Immune Responses.

Vaccination With Tetanus Toxoid and Keyhole Limpet Hemocyanin (KLH) to Assess Antigen-Specific Immune Responses

terminated

The purpose of this study is to learn how the immune system works in response to vaccines. We will give the vaccines to subjects who have cancer but have not had treatment, and to patients who have had chemotherapy or stem cell transplant. Some patients will get vaccines while they are on treatments which boost the immune system (like the immune stimulating drug interleukin-2 or IL-2). Although we have safely treated many patients with immune boosting drugs, we do not yet know if they improve the body's immune system to respond better to a vaccine. Some healthy volunteers will also be given the vaccines in order to serve as control subjects to get a good measure of the normal immune response. We will compare the patients and the healthy volunteers to study how their immune systems respond to the vaccines. There are several different types of white cells in the blood. We are interested in immune cells in the blood called T-cells. These T-cells detect foreign substances in the body (like viruses and cancer cells). We are trying to learn more about how the body fights these foreign substances. Our goal is to develop cancer vaccines which would teach T-cells to detect and kill cancer cells better. We know that in healthy people the immune system effectively protects against recurrent virus infection. For example, that is why people only get "mono" (mononucleosis) once under normal circumstances. When the body is infected with the "mono" virus, the immune system remembers and prevents further infection. We are trying to use the immune system to prevent cancer relapse. To test this, we will give two vaccines which have been used to measure these immune responses. Blood samples will be studied from cancer patients and will be compared to similar samples from normal subjects.

Patients will receive each vaccine once only consisting of: Arm A: Intracel KLH 1000 mcg (1 mg) without adjuvant, subcutaneous Tetanus Toxoid 0.5 ml intramuscularly (this arm closed 1/2/02). Arm B: Biosyn KLH 1000 mcg (1 mg) without adjuvant, subcutaneous tetanus toxoid 0.5 ml intramuscularly (this arm closed 3/18/03). Arm C: Biosyn KLH 1000 mcg (1 mg) with Montanide ISA51 (now replaced with vegetable (VG) source after 8/31/06 to increase product safety) subcutaneous Tetanus toxoid 0.5 ml intramuscularly (this arm open 3/18/03). Subjects ineligible for tetanus may still receive KLH on this protocol. This is especially true given the national shortage of tetanus vaccines. Subjects will be eligible for tetanus when it becomes available if there has been no significant change in treatment interventions or overall health status and it is within 3 months of the KLH vaccine.

0

Replaced by another study.

136

2002-07-01

2012-03-01

actual

0

NCT00000110

Influence of Diet and Endurance Running on Intramuscular Lipids Measured at 4.1 TESLA

completed

treatment

The purpose of this pilot investigation is to use 1 H Magnetic Resonance Spectroscopy (MRS) to 1) document the change in intra-muscular lipid stores (IML) before and after a prolonged bout of endurance running and, 2) determine the pattern (time course) of IML replenishment following an extremely low-fat diet (10% of energy from fat) and a moderate-fat diet (35% of energy from fat). Specifically, the study will evaluate the change in IML following a 2-hour training run and the recovery of IML in response to the post-exercise low-fat or moderate-fat diet in 10 endurance trained athletes who will consume both diets in a randomly assigned cross-over fashion. We hypothesize that IML will be depleted with prolonged endurance exercise, and that replenishment of IML will be impaired by an extremely low-fat diet compared to a moderate-fat diet. Results of this pilot study will be used to apply for extramural grant support from NIH or the US Armed Forces to investigate the effect of dietary fat on the health and performance of individuals performing heavy physical training. It is anticipated that this methodology could also be employed in obesity research to delineate, longitudinally, the reported cross-sectional relationships among IML stores, insulin resistance and obesity.

0

1

NCT00000114

Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa

completed

treatment

To determine whether supplements of vitamin A or vitamin E alone or in combination affect the course of retinitis pigmentosa.

Retinitis pigmentosa (RP) is a group of inherited retinal degenerations with a worldwide prevalence of about 1 in 4,000. Patients typically report night blindness in adolescence and lose vision in the midperipheral followed by far-peripheral visual field in adulthood due to progressive loss of both rod and cone function. Most patients have reductions in central vision by age 50 to 80 years. Modern-day electroretinograms (ERGs) make it possible to record retinal responses from most patients with remaining vision and thereby monitor objectively the course of their disease. While the natural course of retinal degeneration in the common forms of RP was being studied, it was noted that a subgroup of patients aged 18 through 49 who were treating themselves with both vitamin A and vitamin E and other nutritional supplements exhibited less decline in ERG amplitude over a 2-year period. These preliminary findings, as well as the known roles of vitamins A and E in maintaining normal photoreceptor function and structure, prompted this randomized, controlled trial to determine whether these vitamins alone or in combination would halt or slow the progression of the common forms of RP. This study was a randomized, controlled double-masked trial with 2 x 2 factorial design and duration of 4 to 6 years. Patients were assigned to one of four treatment groups: 15,000 IU/day vitamin A 15,000 IU/day vitamin A + 400 IU/day vitamin E trace amounts of both vitamins A and E 400 IU/day of vitamin E The main outcome measure was the 30-Hz cone ERG amplitude. In addition, visual field and visual acuity were measured annually.

0

1984-05-01

1987-06-01

actual

0

NCT00000115

Randomized Trial of Acetazolamide for Uveitis-Associated Cystoid Macular Edema

completed

treatment

To test the efficacy of acetazolamide for the treatment of uveitis-associated cystoid macular edema.

Uveitis, an intraocular inflammatory disease, is the cause of about 10 percent of visual impairment in the United States. Uveitis may lead to many sight-threatening conditions, including cataract, vitreal opacities, glaucoma, and, most commonly, cystoid macular edema. Reduction of swelling or edema within the retina depends on the movement of fluid from the retina through the choroid. A number of studies indicate that this process requires active transport of fluid ions by the retinal pigment epithelium and may involve the carbonic anhydrase system. Current treatment of uveitis-associated cystoid macular edema requires the use of immunosuppressive or anti-inflammatory agents. However, many patients are either resistant or intolerant to this therapy. Recent reports suggested that acetazolamide, a carbonic anhydrase inhibitor that is used to lower intraocular pressure in some glaucoma patients, might be safe and effective in reducing uveitis-associated cystoid macular edema. Because the course of ocular inflammatory disease can be variable, a double-masked, randomized, crossover trial was designed to test the efficacy of acetazolamide compared with a placebo for the treatment of uveitis-associated cystoid macular edema. Randomized adult patients received either oral acetazolamide sodium 500 mg or a matched placebo every 12 hours for the first 4 weeks of the study. Children 8 years of age or older received a lesser dose based on body weight. Following a 4-week period, during which no medication was given, patients then received a 4-week course of the opposite medication. Primary end points included reduction in cystoid macular edema (graded on fluorescein angiography) and improvement in visual acuity (measured on standardized Early Treatment Diabetic Retinopathy Study [ETDRS] charts). Laser acuity was also assessed as a secondary outcome variable. Adverse effects of the acetazolamide therapy were monitored by clinical and laboratory examinations. A total of 40 patients were recruited for the study. Patients were seen at the beginning of the study for baseline measurements and at 4, 8, and 12 weeks after enrollment into the study.

0

1990-12-01

1994-06-01

actual

0

1

Business Decision

The trial was terminated due to a strategic or administrative decision by the sponsor company.

0

6

Change in Medical/Clinical Practices

The study drug was deemed no longer suitable for the target indication due to changes in medical or clinical practices.

0

11

Competing Studies

The study drug is being investigated in other competing trial(s), and continuing this trial was deemed futile.

0

16

Completed

The trial was successfully completed (user input was incorrectly marked as terminated).

0

21

Conflict of Interest

The parties involved had conflicts of interests.

0